{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:31Z","timestamp":1793304871516,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["PRIMUS\/17\/MED\/9; UNCE\/MED\/016; SVV260521"],"award-info":[{"award-number":["PRIMUS\/17\/MED\/9; UNCE\/MED\/016; SVV260521"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Cooperatio"],"award-info":[{"award-number":["Cooperatio"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Cooperatio"],"award-info":[{"award-number":["Cooperatio"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU22-03-00182"],"award-info":[{"award-number":["NU22-03-00182"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU22-03-00182"],"award-info":[{"award-number":["NU22-03-00182"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ-DRO"],"award-info":[{"award-number":["MH CZ-DRO"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00064165"],"award-info":[{"award-number":["00064165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Somatic mutations of genes involved in NF-\u03baB, PI3K\/AKT, NOTCH, and JAK\/STAT signaling pathways play an important role in the pathogenesis of Hodgkin lymphoma (HL). HL tumor cells form only about 5% of the tumor mass; however, it was shown that HL tumor-derived DNA could be detected in the bloodstream. This circulating tumor DNA (ctDNA) reflects the genetic profile of HL tumor cells and can be used for qualitative and quantitative analysis of tumor-specific somatic DNA mutations within the concept of liquid biopsy. Overall, the most frequently mutated gene in HL is <jats:italic>STAT6<\/jats:italic>; however, the exact spectrum of mutations differs between individual HL histological subtypes. Importantly, reduction of ctDNA plasma levels after initial treatment is highly correlated with prognosis. Therefore, ctDNA shows great promise as a novel tool for non-invasive tumor genome analysis for biomarker driven therapy as well as for superior minimal residual disease monitoring and treatment resistance detection. Here, we summarize the recent advancements of ctDNA analysis in HL with focus on ctDNA detection methodologies, genetic profiling of HL and its clonal evolution, and the emerging prognostic value of ctDNA.<\/jats:p>","DOI":"10.1007\/s00277-022-04949-x","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T12:02:43Z","timestamp":1662638563000},"page":"2393-2403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Circulating tumor DNA in Hodgkin lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Maria","family":"Maco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Kupcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Ondeckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Mocikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-3557","authenticated-orcid":false,"given":"Ondrej","family":"Havranek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Czech Hodgkin Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"issue":"20","key":"4949_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"4","key":"4949_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","volume":"184","author":"H Kanzler","year":"1996","unstructured":"Kanzler H, K\u00fcppers R, Hansmann ML et al (1996) Hodgkin and Reed-Sternberg cells in Hodgkin\u2019s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184(4):1495\u20131505. https:\/\/doi.org\/10.1084\/jem.184.4.1495","journal-title":"J Exp Med"},{"issue":"10","key":"4949_CR3","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1172\/jci61245","volume":"122","author":"R K\u00fcppers","year":"2012","unstructured":"K\u00fcppers R, Engert A, Hansmann ML (2012) Hodgkin lymphoma. J Clin Investig 122(10):3439\u20133447. https:\/\/doi.org\/10.1172\/jci61245","journal-title":"J Clin Investig"},{"issue":"3","key":"4949_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","volume":"53","author":"S Mathas","year":"2016","unstructured":"Mathas S, Hartmann S, K\u00fcppers R (2016) Hodgkin lymphoma: pathology and biology. Semin Hematol 53(3):139\u2013147. https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.007","journal-title":"Semin Hematol"},{"issue":"6","key":"4949_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.14735\/amko2014406","volume":"27","author":"L Dusek","year":"2014","unstructured":"Dusek L, Muzik J, Maluskova D et al (2014) Cancer incidence and mortality in the Czech Republic. Klin Onkol 27(6):406\u2013423. https:\/\/doi.org\/10.14735\/amko2014406","journal-title":"Klin Onkol"},{"issue":"1","key":"4949_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors JM, Cozen W, Steidl C et al (2020) Hodgkin lymphoma. Nat Rev Dis Primers 6(1):61. https:\/\/doi.org\/10.1038\/s41572-020-0189-6","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4949_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1470-2045(20)30601-x","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(2):223\u2013234. https:\/\/doi.org\/10.1016\/s1470-2045(20)30601-x","journal-title":"Lancet Oncol"},{"issue":"2","key":"4949_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas RO, Bouabdallah R, Brice P et al (2019) PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20(2):202\u2013215. https:\/\/doi.org\/10.1016\/s1470-2045(18)30784-8","journal-title":"Lancet Oncol"},{"issue":"31","key":"4949_CR9","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/jco.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C et al (2019) Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol 37(31):2835\u20132845. https:\/\/doi.org\/10.1200\/jco.19.00964","journal-title":"J Clin Oncol"},{"issue":"21","key":"4949_CR10","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.7150\/jca.29308","volume":"10","author":"Z Kral","year":"2019","unstructured":"Kral Z, Michalka J, Mocikova H et al (2019) Treatment of relapsed\/refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia. J Cancer 10(21):5041\u20135048. https:\/\/doi.org\/10.7150\/jca.29308","journal-title":"J Cancer"},{"key":"4949_CR11","doi-asserted-by":"publisher","unstructured":"Mocikova H, Markova J, Gaherova L et al [Treatment of relapsed and refractory Hodgkin lymphoma - recommendations of the Czech Hodgkin lymphoma study group]. Klin Onkol 29 (5):342\u2013346. https:\/\/doi.org\/10.14735\/amko2016342","DOI":"10.14735\/amko2016342"},{"issue":"6","key":"4949_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14735\/amko2014424","volume":"27","author":"H Mocikova","year":"2014","unstructured":"Mocikova H, Sykorova A, Stepankova P et al (2014) Treatment and prognosis of relapsed or refractory Hodgkin lymphoma patients ineligible for stem cell transplantation. Klin Onkol 27(6):424\u2013428. https:\/\/doi.org\/10.14735\/amko2014424","journal-title":"Klin Onkol"},{"issue":"1","key":"4949_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1200\/jco.2002.20.1.221","volume":"20","author":"A Josting","year":"2002","unstructured":"Josting A, Franklin J, May M et al (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 20(1):221\u2013230. https:\/\/doi.org\/10.1200\/jco.2002.20.1.221","journal-title":"J Clin Oncol"},{"issue":"7","key":"4949_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119(7):1665\u20131670. https:\/\/doi.org\/10.1182\/blood-2011-10-388058","journal-title":"Blood"},{"issue":"3","key":"4949_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.v97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97(3):616\u2013623. https:\/\/doi.org\/10.1182\/blood.v97.3.616","journal-title":"Blood"},{"issue":"1","key":"4949_CR16","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.053","volume":"6","author":"A Cuccaro","year":"2014","unstructured":"Cuccaro A, Bartolomei F, Cupelli E et al (2014) Prognostic factors in hodgkin lymphoma. Mediterr J Hematol Infect Dis 6(1):e2014053. https:\/\/doi.org\/10.4084\/mjhid.2014.053","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"4949_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11899-015-0262-5","volume":"10","author":"PJ Br\u00f6ckelmann","year":"2015","unstructured":"Br\u00f6ckelmann PJ, Engert A (2015) The GHSG approach to treating Hodgkin\u2019s lymphoma. Curr Hematol Malig Rep 10(3):256\u2013265. https:\/\/doi.org\/10.1007\/s11899-015-0262-5","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"4949_CR18","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/nejm199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (21):1506\u20131514.https:\/\/doi.org\/10.1056\/nejm199811193392104","journal-title":"N Engl J Med"},{"issue":"2","key":"4949_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-019-03893-7","volume":"99","author":"A Bari","year":"2020","unstructured":"Bari A, Marcheselli R, Sacchi S et al (2020) The classic prognostic factors in advanced Hodgkin\u2019s lymphoma patients are losing their meaning at the time of pet-guided treatments. Ann Hematol 99(2):277\u2013282. https:\/\/doi.org\/10.1007\/s00277-019-03893-7","journal-title":"Ann Hematol"},{"key":"4949_CR20","doi-asserted-by":"publisher","unstructured":"Eichenauer DA, Engert A, Dreyling M (2011) Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi55-58. https:\/\/doi.org\/10.1093\/annonc\/mdr37","DOI":"10.1093\/annonc\/mdr37"},{"issue":"27","key":"4949_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"21","key":"4949_CR22","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"issue":"1","key":"4949_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52\u201359. https:\/\/doi.org\/10.1182\/blood-2005-06-2252","journal-title":"Blood"},{"issue":"9","key":"4949_CR24","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A et al (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41(9):1735\u20131743. https:\/\/doi.org\/10.1007\/s00259-014-2783-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4949_CR25","doi-asserted-by":"publisher","first-page":"CD012643","DOI":"10.1002\/14651858.CD012643.pub2","volume":"9","author":"A Aldin","year":"2019","unstructured":"Aldin A, Umlauff L, Estcourt LJ et al (2019) Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev 9:CD012643. https:\/\/doi.org\/10.1002\/14651858.CD012643.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"4949_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.2967\/jnumed.117.192294","volume":"58","author":"HJA Adams","year":"2017","unstructured":"Adams HJA, Kwee TC (2017) Reply: interim PET in Hodgkin lymphoma: is it so useless? J Nucl Med 58(7):1180\u20131182. https:\/\/doi.org\/10.2967\/jnumed.117.192294","journal-title":"J Nucl Med"},{"issue":"12","key":"4949_CR27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/jco.2013.51.9298","volume":"32","author":"JM Raemaekers","year":"2014","unstructured":"Raemaekers JM, Andr\u00e9 MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 32(12):1188\u20131194. https:\/\/doi.org\/10.1200\/jco.2013.51.9298","journal-title":"J Clin Oncol"},{"issue":"17","key":"4949_CR28","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372(17):1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"issue":"16","key":"4949_CR29","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/jco.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35(16):1786\u20131794. https:\/\/doi.org\/10.1200\/jco.2016.68.6394","journal-title":"J Clin Oncol"},{"issue":"10114","key":"4949_CR30","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/s0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann P, Goergen H, Kobe C et al (2018) PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet 390(10114):2790\u20132802. https:\/\/doi.org\/10.1016\/s0140-6736(17)32134-7","journal-title":"Lancet"},{"issue":"9828","key":"4949_CR31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/s0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791\u20131799. https:\/\/doi.org\/10.1016\/s0140-6736(11)61940-5","journal-title":"Lancet"},{"issue":"25","key":"4949_CR32","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374(25):2419\u20132429. https:\/\/doi.org\/10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"4949_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ncomms1180","volume":"2","author":"L Balaj","year":"2011","unstructured":"Balaj L, Lessard R, Dai L et al (2011) Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2:180. https:\/\/doi.org\/10.1038\/ncomms1180","journal-title":"Nat Commun"},{"issue":"13","key":"4949_CR34","doi-asserted-by":"publisher","first-page":"E1826","DOI":"10.1073\/pnas.1519286113","volume":"113","author":"R Lehmann-Werman","year":"2016","unstructured":"Lehmann-Werman R, Neiman D, Zemmour H et al (2016) Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci USA 113(13):E1826-1834. https:\/\/doi.org\/10.1073\/pnas.1519286113","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4949_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.molonc.2014.02.005","volume":"8","author":"F Mouliere","year":"2014","unstructured":"Mouliere F, El Messaoudi S, Pang D et al (2014) Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol 8(5):927\u2013941. https:\/\/doi.org\/10.1016\/j.molonc.2014.02.005","journal-title":"Mol Oncol"},{"issue":"2","key":"4949_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1101\/gr.275691.121","volume":"32","author":"I Hudecova","year":"2022","unstructured":"Hudecova I, Smith CG, H\u00e4nsel-Hertsch R et al (2022) Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. Genome Res 32(2):215\u2013227. https:\/\/doi.org\/10.1101\/gr.275691.121","journal-title":"Genome Res"},{"key":"4949_CR37","doi-asserted-by":"publisher","first-page":"27859","DOI":"10.1038\/srep27859","volume":"6","author":"P Burnham","year":"2016","unstructured":"Burnham P, Kim MS, Agbor-Enoh S et al (2016) Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Sci Rep 6:27859. https:\/\/doi.org\/10.1038\/srep27859","journal-title":"Sci Rep"},{"issue":"1","key":"4949_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s13402-018-0413-5","volume":"42","author":"H Fettke","year":"2019","unstructured":"Fettke H, Kwan EM, Azad AA (2019) Cell-free DNA in cancer: current insights. Cell Oncol (Dordr) 42(1):13\u201328. https:\/\/doi.org\/10.1007\/s13402-018-0413-5","journal-title":"Cell Oncol (Dordr)"},{"key":"4949_CR39","doi-asserted-by":"publisher","first-page":"117727191982654","DOI":"10.1177\/1177271919826545","volume":"14","author":"BA Sisson","year":"2019","unstructured":"Sisson BA, Uvalic J, Kelly K et al (2019) Technical and regulatory considerations for taking liquid biopsy to the clinic: validation of the JAX PlasmaMonitor(TM) assay. Biomark Insights 14:1177271919826545. https:\/\/doi.org\/10.1177\/1177271919826545","journal-title":"Biomark Insights"},{"issue":"11","key":"4949_CR40","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/cancers13112652","volume":"13","author":"M Oshi","year":"2021","unstructured":"Oshi M, Murthy V, Takahashi H et al (2021) Urine as a source of liquid biopsy for cancer. Cancers 13(11):2652","journal-title":"Cancers"},{"issue":"7","key":"4949_CR41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jmoldx.2020.04.208","volume":"22","author":"Z Wang","year":"2020","unstructured":"Wang Z, Zhang L, Li L et al (2020) Sputum cell-free DNA: valued surrogate sample for detection of EGFR mutation in patients with advanced lung adenocarcinoma. J Mol Diagn 22(7):934\u2013942. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.04.208","journal-title":"J Mol Diagn"},{"issue":"2","key":"4949_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3324\/haematol.2019.241208","volume":"106","author":"B Sabela","year":"2020","unstructured":"Sabela B, Marta C, Laura E et al (2020) Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica 106(2):513\u2013521. https:\/\/doi.org\/10.3324\/haematol.2019.241208","journal-title":"Haematologica"},{"key":"4949_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100449","volume":"29","author":"R de Kock","year":"2021","unstructured":"de Kock R, Knoops C, Baselmans M et al (2021) Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients. Cancer Treat Res Commun 29:100449. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100449","journal-title":"Cancer Treat Res Commun"},{"issue":"9","key":"4949_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256979","volume":"16","author":"Y Cui","year":"2021","unstructured":"Cui Y, Kim HS, Cho ES et al (2021) Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas. PLoS ONE 16(9):e0256979. https:\/\/doi.org\/10.1371\/journal.pone.0256979","journal-title":"PLoS ONE"},{"issue":"6","key":"4949_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00428-019-02571-3","volume":"474","author":"ZC Deans","year":"2019","unstructured":"Deans ZC, Butler R, Cheetham M et al (2019) IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Virchows Arch 474(6):681\u2013689. https:\/\/doi.org\/10.1007\/s00428-019-02571-3","journal-title":"Virchows Arch"},{"issue":"6 Pt 1","key":"4949_CR46","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1373\/49.6.1028","volume":"49","author":"M Jung","year":"2003","unstructured":"Jung M, Klotzek S, Lewandowski M et al (2003) Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 49(6 Pt 1):1028\u20131029. https:\/\/doi.org\/10.1373\/49.6.1028","journal-title":"Clin Chem"},{"issue":"10","key":"4949_CR47","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/cam4.1184","volume":"6","author":"JH van Ginkel","year":"2017","unstructured":"van Ginkel JH, van den Broek DA, van Kuik J et al (2017) Preanalytical blood sample workup for cell-free DNA analysis using droplet digital PCR for future molecular cancer diagnostics. Cancer Med 6(10):2297\u20132307. https:\/\/doi.org\/10.1002\/cam4.1184","journal-title":"Cancer Med"},{"issue":"6","key":"4949_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jmoldx.2018.07.005","volume":"20","author":"B Risberg","year":"2018","unstructured":"Risberg B, Tsui DWY, Biggs H et al (2018) Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients. J Mol Diagn 20(6):883\u2013892. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.07.005","journal-title":"J Mol Diagn"},{"issue":"4","key":"4949_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/gtmb.2018.0189","volume":"23","author":"S Jain","year":"2019","unstructured":"Jain S, Lin SY, Song W et al (2019) Urine-based liquid biopsy for nonurological cancers. Genet Test Mol Biomarkers 23(4):277\u2013283. https:\/\/doi.org\/10.1089\/gtmb.2018.0189","journal-title":"Genet Test Mol Biomarkers"},{"issue":"Supplement 1","key":"4949_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2021-149644","volume":"138","author":"JA Mutter","year":"2021","unstructured":"Mutter JA, Alig S, Lauer EM et al (2021) Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma. Blood 138(Supplement 1):6\u20136. https:\/\/doi.org\/10.1182\/blood-2021-149644","journal-title":"Blood"},{"issue":"2","key":"4949_CR51","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey MH, Tokheim C, Porta-Pardo E et al (2018) Comprehensive characterization of cancer driver genes and mutations. Cell 173(2):371-385.e318. https:\/\/doi.org\/10.1016\/j.cell.2018.02.060","journal-title":"Cell"},{"issue":"13","key":"4949_CR52","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1039\/c1lc20126c","volume":"11","author":"Q Zhong","year":"2011","unstructured":"Zhong Q, Bhattacharya S, Kotsopoulos S et al (2011) Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip 11(13):2167\u20132174. https:\/\/doi.org\/10.1039\/c1lc20126c","journal-title":"Lab Chip"},{"issue":"2","key":"4949_CR53","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/10428194.2018.1492123","volume":"60","author":"B Lea","year":"2019","unstructured":"Lea B (2019) Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma\u201d. Leuk Lymphoma 60(2):498\u2013502","journal-title":"Leuk Lymphoma"},{"key":"4949_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.579762","volume":"10","author":"R Appay","year":"2020","unstructured":"Appay R, Fina F, Barets D et al (2020) Multiplexed droplet digital PCR assays for the simultaneous screening of major genetic alterations in tumors of the central nervous system. Front Oncol 10:579762. https:\/\/doi.org\/10.3389\/fonc.2020.579762","journal-title":"Front Oncol"},{"issue":"4","key":"4949_CR55","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.14616","volume":"177","author":"M Cavalli","year":"2017","unstructured":"Cavalli M, De Novi LA, Della Starza I et al (2017) Comparative analysis between RQ-PCR and digital droplet PCR of BCL2\/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol 177(4):588\u2013596. https:\/\/doi.org\/10.1111\/bjh.14616","journal-title":"Br J Haematol"},{"issue":"5","key":"4949_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jmoldx.2015.04.002","volume":"17","author":"Q Wang","year":"2015","unstructured":"Wang Q, Yang X, He Y et al (2015) Droplet digital PCR for absolute quantification of EML4-ALK gene rearrangement in lung adenocarcinoma. J Mol Diagn 17(5):515\u2013520. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.04.002","journal-title":"J Mol Diagn"},{"issue":"1","key":"4949_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3324\/haematol.2019.237719","volume":"106","author":"V Camus","year":"2021","unstructured":"Camus V, Viennot M, Lequesne J et al (2021) Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica 106(1):154\u2013162. https:\/\/doi.org\/10.3324\/haematol.2019.237719","journal-title":"Haematologica"},{"issue":"5","key":"4949_CR58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM, Lovejoy AF, Klass DM et al (2016) Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34(5):547\u2013555. https:\/\/doi.org\/10.1038\/nbt.3520","journal-title":"Nat Biotechnol"},{"issue":"11","key":"4949_CR59","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/nprot.2014.170","volume":"9","author":"SR Kennedy","year":"2014","unstructured":"Kennedy SR, Schmitt MW, Fox EJ et al (2014) Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc 9(11):2586\u20132606. https:\/\/doi.org\/10.1038\/nprot.2014.170","journal-title":"Nat Protoc"},{"issue":"5","key":"4949_CR60","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548\u2013554. https:\/\/doi.org\/10.1038\/nm.3519","journal-title":"Nat Med"},{"issue":"12","key":"4949_CR61","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L et al (2021) Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39(12):1537\u20131547. https:\/\/doi.org\/10.1038\/s41587-021-00981-w","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4949_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.15614","volume":"184","author":"HW Wang","year":"2019","unstructured":"Wang HW, Balakrishna JP, Pittaluga S et al (2019) Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol 184(1):45\u201359. https:\/\/doi.org\/10.1111\/bjh.15614","journal-title":"Br J Haematol"},{"issue":"9","key":"4949_CR63","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus V, Stamatoullas A, Mareschal S et al (2016) Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 101(9):1094\u20131101. https:\/\/doi.org\/10.3324\/haematol.2016.145102","journal-title":"Haematologica"},{"issue":"4","key":"4949_CR64","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger MA, K\u00fcppers R (2021) Molecular biology of Hodgkin lymphoma. Leukemia 35(4):968\u2013981. https:\/\/doi.org\/10.1038\/s41375-021-01204-6","journal-title":"Leukemia"},{"issue":"7","key":"4949_CR65","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel J, Chadburn A, Rubinstein PG et al (2015) Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125(7):1061\u20131072. https:\/\/doi.org\/10.1182\/blood-2014-11-610436","journal-title":"Blood"},{"issue":"22","key":"4949_CR66","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci E, Ladewig E, Schiavoni G et al (2018) Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood 131(22):2454\u20132465. https:\/\/doi.org\/10.1182\/blood-2017-11-814913","journal-title":"Blood"},{"issue":"23","key":"4949_CR67","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand K, Chapuy B, Stewart C et al (2019) Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv 3(23):4065\u20134080. https:\/\/doi.org\/10.1182\/bloodadvances.2019001012","journal-title":"Blood Adv"},{"issue":"2","key":"4949_CR68","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/10428194.2018.1492123","volume":"60","author":"L Bessi","year":"2019","unstructured":"Bessi L, Viailly PJ, Bohers E et al (2019) Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma. Leuk Lymphoma 60(2):498\u2013502. https:\/\/doi.org\/10.1080\/10428194.2018.1492123","journal-title":"Leuk Lymphoma"},{"key":"4949_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0541-6","author":"AK Desch","year":"2019","unstructured":"Desch AK, Hartung K, Botzen A et al (2019) Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. https:\/\/doi.org\/10.1038\/s41375-019-0541-6","journal-title":"Leukemia"},{"issue":"7338","key":"4949_CR70","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, Shah SP, Woolcock BW et al (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471(7338):377\u2013381. https:\/\/doi.org\/10.1038\/nature09754","journal-title":"Nature"},{"issue":"23","key":"4949_CR71","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/jco.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH et al (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34(23):2690\u20132697. https:\/\/doi.org\/10.1200\/jco.2016.66.4482","journal-title":"J Clin Oncol"},{"issue":"22","key":"4949_CR72","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A et al (2018) Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131(22):2413\u20132425. https:\/\/doi.org\/10.1182\/blood-2017-11-812073","journal-title":"Blood"},{"issue":"1","key":"4949_CR73","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/path.2384","volume":"216","author":"M Vockerodt","year":"2008","unstructured":"Vockerodt M, Morgan SL, Kuo M et al (2008) The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin\u2019s Reed-Sternberg-like phenotype. J Pathol 216(1):83\u201392. https:\/\/doi.org\/10.1002\/path.2384","journal-title":"J Pathol"},{"issue":"4","key":"4949_CR74","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/leu.2015.328","volume":"30","author":"S Hartmann","year":"2016","unstructured":"Hartmann S, Schuhmacher B, Rausch T et al (2016) Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia 30(4):844\u2013853. https:\/\/doi.org\/10.1038\/leu.2015.328","journal-title":"Leukemia"},{"issue":"2","key":"4949_CR75","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2002-05-1592","volume":"101","author":"I Wlodarska","year":"2003","unstructured":"Wlodarska I, Nooyen P, Maes B et al (2003) Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 101(2):706\u2013710. https:\/\/doi.org\/10.1182\/blood-2002-05-1592","journal-title":"Blood"},{"issue":"8","key":"4949_CR76","first-page":"965","volume":"89","author":"I Wlodarska","year":"2004","unstructured":"Wlodarska I, Stul M, De Wolf-Peeters C et al (2004) Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin\u2019s lymphoma. Haematologica 89(8):965\u2013972","journal-title":"Haematologica"},{"issue":"3","key":"4949_CR77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3816\/CLM.2009.n.042","volume":"9","author":"H Mani","year":"2009","unstructured":"Mani H, Jaffe ES (2009) Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma 9(3):206\u2013216. https:\/\/doi.org\/10.3816\/CLM.2009.n.042","journal-title":"Clin Lymphoma Myeloma"},{"issue":"9","key":"4949_CR78","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1182\/blood-2007-03-082511","volume":"110","author":"A Mottok","year":"2007","unstructured":"Mottok A, Renne C, Willenbrock K et al (2007) Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110(9):3387\u20133390. https:\/\/doi.org\/10.1182\/blood-2007-03-082511","journal-title":"Blood"},{"issue":"1","key":"4949_CR79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3324\/haematol.2009.010157","volume":"95","author":"MA Schumacher","year":"2010","unstructured":"Schumacher MA, Schmitz R, Brune V et al (2010) Mutations in the genes coding for the NF-kappaB regulating factors IkappaBalpha and A20 are uncommon in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma. Haematologica 95(1):153\u2013157. https:\/\/doi.org\/10.3324\/haematol.2009.010157","journal-title":"Haematologica"},{"issue":"5","key":"4949_CR80","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/s0002-9440(10)64462-8","volume":"161","author":"S Franke","year":"2002","unstructured":"Franke S, Wlodarska I, Maes B et al (2002) Comparative genomic hybridization pattern distinguishes T-cell\/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin\u2019s lymphoma. Am J Pathol 161(5):1861\u20131867. https:\/\/doi.org\/10.1016\/s0002-9440(10)64462-8","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"4949_CR81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/13.s1.44","volume":"13","author":"T Rudiger","year":"2002","unstructured":"Rudiger T, Gascoyne RD, Jaffe ES et al (2002) Workshop on the relationship between nodular lymphocyte predominant Hodgkin\u2019s lymphoma and T cell\/histiocyte-rich B cell lymphoma. Ann Oncol 13(Suppl 1):44\u201351. https:\/\/doi.org\/10.1093\/annonc\/13.s1.44","journal-title":"Ann Oncol"},{"issue":"3","key":"4949_CR82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjh.13310","volume":"169","author":"S Hartmann","year":"2015","unstructured":"Hartmann S, D\u00f6ring C, Vucic E et al (2015) Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma. Br J Haematol 169(3):415\u2013422. https:\/\/doi.org\/10.1111\/bjh.13310","journal-title":"Br J Haematol"},{"issue":"1","key":"4949_CR83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","volume":"34","author":"AK Desch","year":"2020","unstructured":"Desch AK, Hartung K, Botzen A et al (2020) Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia 34(1):151\u2013166. https:\/\/doi.org\/10.1038\/s41375-019-0541-6","journal-title":"Leukemia"},{"issue":"4","key":"4949_CR84","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bjh.17719","volume":"195","author":"M Alcoceba","year":"2021","unstructured":"Alcoceba M, Garc\u00eda-\u00c1lvarez M, Chill\u00f3n MC et al (2021) Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. Br J Haematol 195(4):542\u2013551. https:\/\/doi.org\/10.1111\/bjh.17719","journal-title":"Br J Haematol"},{"issue":"10","key":"4949_CR85","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","volume":"2","author":"S Sobesky","year":"2021","unstructured":"Sobesky S, Mammadova L, Cirillo M et al (2021) In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection. Med 2(10):1171-1193.e1111. https:\/\/doi.org\/10.1016\/j.medj.2021.09.002","journal-title":"Med"},{"key":"4949_CR86","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/hs9.0000000000000404","volume":"4","author":"M Di Trani","year":"2020","unstructured":"Di Trani M, Rizzo E, Calabretta E et al (2020) Assesment of circulating tumor DNA in patients with relapsed\/refractory Hodgkin lymphoma: early identification of pattern of mutations associated with response or resistance to PD-1 inhibitros, Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020. HemaSphere 4:606. https:\/\/doi.org\/10.1097\/hs9.0000000000000404","journal-title":"HemaSphere"},{"key":"4949_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102731","volume":"54","author":"Y Shi","year":"2020","unstructured":"Shi Y, Su H, Song Y et al (2020) Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine 54:102731. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102731","journal-title":"EBioMedicine"},{"issue":"14","key":"4949_CR88","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E et al (2017) Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 129(14):1947\u20131957. https:\/\/doi.org\/10.1182\/blood-2016-05-719641","journal-title":"Blood"},{"key":"4949_CR89","doi-asserted-by":"publisher","unstructured":"Di Trani M, Rizzo E, Locatelli S et al (2019) Longitudinal assessment of circulating tumor mutational burden using a next-generation sequencing cancer gene panel: a potential biomarker of response to programmed cell death 1 (PD-1) blockade in patients with relapsed\/refractory classical Hodgkin lymphoma. Blood 134. https:\/\/doi.org\/10.1182\/blood-2019-131096","DOI":"10.1182\/blood-2019-131096"},{"issue":"1","key":"4949_CR90","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13550-020-00717-y","volume":"10","author":"P Decazes","year":"2020","unstructured":"Decazes P, Camus V, Bohers E et al (2020) Correlations between baseline (18)F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma. EJNMMI Res 10(1):120. https:\/\/doi.org\/10.1186\/s13550-020-00717-y","journal-title":"EJNMMI Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04949-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04949-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04949-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:04:48Z","timestamp":1665119088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04949-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":90,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4949"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04949-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.K. and H.M. received consultancy fees, advisory board participation fees, travel grants, and honoraria from Takeda, Janssen, Gilead, Roche, AstraZeneca, AbbVie, and Bristol Meyer Squibb. O.H. has received research support from Bristol Meyer Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-financial interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}